{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Hsu CC"],"funding":["Taipei Veterans General Hospital","National Science and Technology Council","Gilead Sciences"],"pubmed_abstract":["<h4>Introduction</h4>Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB). Real-world monitoring of patients on these agents and their comparative renal safety remain poorly characterized. We evaluated guideline-adherent monitoring practices and compared renal dysfunction risk across ETV, TDF, and TAF.<h4>Methods</h4>We retrospectively analyzed patients with CHB who initiated ETV, TDF, or TAF between 2012 and 2022. Levels of serum alanine aminotransferase, total bilirubin, albumin, serum creatinine, hepatitis B virus DNA, and abdominal sonograms were assessed every 6 months during the 36 months of NA treatment. Incidence rates and adjusted hazard ratios (HRs) for renal dysfunction were "],"journal":["Clinical and translational gastroenterology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12922928"],"repository":["biostudies-literature"],"pubmed_title":["Monitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B."],"pmcid":["PMC12922928"],"funding_grant_id":["V111B-043, V111EA-017, V113C-141, V114C-234, V115C-246, Center of Excellence for Cancer Research MOHW112-TDU-B-221-124007, Y.L. Lin Hung Tai Education Foundation, and Big Data Center.","CO-TW-988-6355","MOST 111-2635-B-075-001, NSTC 112-2314-B-075-043-MY2"],"pubmed_authors":["Chou CY","Hsu CC","Chang YL","Chou YC","Wu JC","Su CW","Chen ZE","Hou MC","Chao FH"],"additional_accession":[]},"is_claimable":false,"name":"Monitoring Adherence and Renal Safety of Nucleos(t)ide Analogs for Patients With Chronic Hepatitis B.","description":"<h4>Introduction</h4>Entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB). Real-world monitoring of patients on these agents and their comparative renal safety remain poorly characterized. We evaluated guideline-adherent monitoring practices and compared renal dysfunction risk across ETV, TDF, and TAF.<h4>Methods</h4>We retrospectively analyzed patients with CHB who initiated ETV, TDF, or TAF between 2012 and 2022. Levels of serum alanine aminotransferase, total bilirubin, albumin, serum creatinine, hepatitis B virus DNA, and abdominal sonograms were assessed every 6 months during the 36 months of NA treatment. Incidence rates and adjusted hazard ratios (HRs) for renal dysfunction were ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-07-16T12:57:28.17Z","creation":"2026-07-09T10:56:37.695Z"},"accession":"S-EPMC12922928","cross_references":{"pubmed":["41363729"],"doi":["10.14309/ctg.0000000000000962"]}}